Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RSMDF) EBT (2016 - 2025)

Historic EBT for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to $496.1 million.

  • Resmed's EBT rose 1860.43% to $496.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year increase of 1848.34%. This contributed to the annual value of $1.7 billion for FY2025, which is 3263.51% up from last year.
  • Per Resmed's latest filing, its EBT stood at $496.1 million for Q4 2025, which was up 1860.43% from $446.8 million recorded in Q3 2025.
  • Resmed's 5-year EBT high stood at $496.1 million for Q4 2025, and its period low was $218.0 million during Q1 2021.
  • Moreover, its 5-year median value for EBT was $275.2 million (2022), whereas its average is $320.2 million.
  • In the last 5 years, Resmed's EBT tumbled by 520.19% in 2023 and then surged by 6123.17% in 2024.
  • Over the past 5 years, Resmed's EBT (Quarter) stood at $237.3 million in 2021, then rose by 15.34% to $273.7 million in 2022, then fell by 5.2% to $259.5 million in 2023, then surged by 61.23% to $418.3 million in 2024, then increased by 18.6% to $496.1 million in 2025.
  • Its EBT was $496.1 million in Q4 2025, compared to $446.8 million in Q3 2025 and $458.1 million in Q2 2025.